Business Context and Reporting Period
Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 31, 2026
Business Overview: The Company operates two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care). The Company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric (in millions) | Three Months Ended July 31, 2026 |
Three Months Ended July 31, 2025 |
Nine Months Ended July 31, 2026 |
Nine Months Ended July 31, 2025 |
|---|---|---|---|---|
| Net Sales | $1,066.2 | $1,060.3 | $3,171.8 | $3,027.3 |
| Gross Profit | $711.9 | $692.0 | $2,142.5 | $2,031.3 |
| Gross Margin | 67% | 65% | 68% | 67% |
| Operating Income | $222.0 | $175.7 | $403.8 | $542.5 |
| Net Income | $432.8 | $98.3 | $485.7 | $290.3 |
| Diluted EPS | $2.24 | $0.49 | $2.49 | $1.45 |
| Operating Cash Flow | N/A | N/A | $785.4 | $548.2 |
| Total Debt | $2,544.2 | N/A | N/A | N/A |
| Cash & Equivalents | $154.7 | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Net Income Surge: Net income for the three months ended July 31, 2026, increased to $432.8 million from $98.3 million in the prior year. This was primarily driven by a discrete income tax benefit of $307.2 million resulting from the favorable resolution of a UK tax authority examination regarding an intra-group IP transfer.
- Operating Income Variance: While operating income increased 26% year-over-year for the quarter ($222.0M vs $175.7M), it decreased 26% for the nine-month period ($403.8M vs $542.5M). The nine-month decline was largely due to a $272.0 million litigation expense (net of insurance) recorded in the CooperSurgical segment.
- Segment Performance:
- CooperVision: Net sales were flat for the quarter but grew 5% for the nine months. Operating income increased in both periods due to expense reductions and sales growth.
- CooperSurgical: Net sales grew 2% (quarter) and 4% (nine months). However, the segment reported an operating loss of $157.1 million for the nine months, compared to income of $39.7 million in the prior year, driven by the aforementioned litigation accrual.
- Debt Structure: Short-term debt increased significantly to $628.1 million from $47.8 million at the prior fiscal year-end, while long-term debt decreased to $1.916 billion from $2.458 billion. The Company extended the maturity of $950 million of term loans to 2031.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term prospects in contact lens and general healthcare markets. Growth is expected to be driven by silicone hydrogel product adoption and myopia management solutions (e.g., MiSight).
- Share Repurchases: In September 2026 (subsequent to the period end), the Board increased the share repurchase authorization by $1.0 billion to a total of $3.0 billion. Approximately $1.5 billion remains authorized.
- Material Risks & Contingencies:
- CooperSurgical Litigation: The Company settled substantially all claims related to the LifeGlobal embryo culture media recall in August 2026 for $306.8 million (with $43.8 million paid by insurance). The accrual was consistent with estimates.
- UK Tax Dispute: The Company is appealing a UK First-tier Tribunal decision regarding payroll tax withholding on the 2014 Sauflon acquisition. A loss is not considered probable, but a range of £0 to £71.7 million is reasonably possible.
- Market Risks: Exposure to foreign currency fluctuations (10% change could impact operating income by ~$29.5 million) and variable interest rates on debt.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the non-recurring nature of the $307.2 million tax benefit and its impact on normalized earnings.
- Litigation Resolution: Confirm that the August 2026 settlement of the CooperSurgical recall claims fully resolves the exposure and that no further claims are anticipated.
- UK Tax Appeal: Monitor the status of the appeal regarding the Sauflon acquisition payroll tax dispute for potential future liabilities.
- Debt Maturity Profile: Review the impact of the extended term loan maturity (2031) on future interest expense and liquidity.
- CooperSurgical Turnaround: Assess whether the segment can return to profitability without the drag of the litigation expense in future periods.